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Gastric Banding Surgery versus Continuous Positive
Airway Pressure for Obstructive Sleep Apnea:
A Randomized Controlled Trial
To the Editor:
We performed a randomized trial of continuous positive airway
pressure (CPAP) versus laparoscopic gastric banding (LGB) for
patients with severe obstructive sleep apnea (OSA), hypothesizing
that residual disease (effective apnea–hypopnea index [AHI])
(1–3) and Epworth Sleepiness Scale (ESS) scores would be
signiﬁcantly lower with LGB compared with CPAP at 9 and
18 months. Approval was obtained from the institutional review
boards at Brigham and Women’s Hospital and Beth Israel Deaconess
Medical Center. The protocol was registered at clinicaltrials.gov
(NCT01187771). All participants gave written informed consent.
The inclusion criteria were age 18–65 years, body mass index
(BMI) 35–45 kg/m2, severe OSA (AHI > 30 events/h [level 1
study] or AHI > 20 events/h [level 3 study]), and at least one OSA
symptom. The exclusion criteria were prior CPAP or bariatric
surgery, hypoventilation syndrome, increased perioperative risk,
drowsy driving, non-English ﬂuency, or any unstable medical
condition. Suitability for both treatments, as well as the equipoise
of each patient, was established by a sleep specialist and bariatrician
before consent was obtained.
Patients underwent attended polysomnography using the
Compumedics E-Series at baseline, 9 months, and 18 months.
Randomization was stratiﬁed by recruitment clinic, baseline
BMI (35–40 or 40–45 kg/m2), and sex. Sequences had block sizes of
two and four, with a 50% chance of choosing either one.

Supported by NIH grants R01HL106410 and K24HL127307 (S.R.P.). Philips
Respironics donated the CPAP machines and supplies used in the
perioperative period for patients undergoing bariatric surgery.
Author Contributions: Study design: A.T., A.M., and S.R.P. Study conduct and data
collection: J.P.B., A.T., M.R., R.A., A.M., R.L.O., A.A., K.A.D., and S.R.P. Analysis
and interpretation: J.P.B., A.T., M.R., K.A.D., W.W., and S.R.P. Manuscript
preparation: J.P.B., M.R., R.A., A.M., R.L.O., A.A., K.A.D., W.W., and S.R.P.
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Initiation and management of OSA care once treatment was
assigned were performed by the managing clinician as per usual
care, except that patients undergoing LGB were provided autoCPAP (REMstar Auto M Series; Philips Respironics) during the
perioperative period to minimize OSA complications. The effective
AHI was calculated as (x 3 AHIon-CPAP) 1 [(1 2 x) 3 AHIoff-CPAP],
where x is (CPAP adherence)/(habitual sleep duration) (3).
Adherence and AHIon-CPAP were downloaded from the device
and averaged across the previous 30 days. AHIoff-CPAP was
calculated from polysomnography data obtained at 9 or
18 months.
We performed an a priori power analysis to determine the
difference in effective AHI between arms, indicating a sample
size of 80. With the support of our Data Safety Monitoring Board
and approval from the NHLBI, we performed a second power
calculation while the study was underway. We assumed a mean
baseline AHI [mean 6 SD] of 50 6 10 events/h. In the CPAP
group, we assumed a mean CPAP adherence of 4 h/night and
usual sleep duration of 8 h/night, resulting in an effective AHI of
25 events/h. In the LGB group, based on a published meta-analysis,
we anticipated a 31% reduction in AHI, resulting in an effective AHI
of 35 events/h (4). Under these assumptions, we would have .90%
power to detect a beneﬁt of LGB with a sample size of 50.
We made between-arm comparisons using linear models with
prespeciﬁed adjustments for randomization stratiﬁcation factors.
Within-arm comparisons were based on the difference between
baseline and end-trial data, using one-sample t tests or signed-rank
tests. Tests were considered statistically signiﬁcant when P , 0.05
(two-sided).
Figure 1 shows that 49 patients were randomized. In the LGB
group, 14/28 underwent LGB only (50%), 10 underwent CPAP
only (36%), and four underwent neither (14%). In the CPAP group,
20/21 received CPAP only (95%), and one began CPAP followed
by gastric bypass surgery (5%).
LGB was associated with a greater drop in BMI (Table 1).
In intention-to-treat analyses, the effective AHI at 9 months was
29.5 6 23.4 and 20.0 6 25.3 events/h in the LGB and CPAP groups,
respectively (P = 0.02). At 18 months, the effective AHI was 20.9 6
16.0 and 21.4 6 17.6 events/h (P = 0.89). Although there were
signiﬁcant improvements in ESS scores with both treatments, there
were no signiﬁcant differences between arms. Self-reported sleep
durations were 7.4 6 1.4, 7.4 6 1.3, and 7.3 6 1.2 h/night at
baseline, 9 months, and 18 months, respectively, in the surgery
arm, and 8.5 6 1.8, 8.0 6 1.4, and 8.4 6 1.5 h/night, respectively,
in the CPAP arm.
Analyses limited to patients who received their assigned
treatment (n = 14 LGB; n = 20 CPAP) produced similar results, that is,
a greater improvement in effective AHI with CPAP (18.6 6 25.3 vs.
28.2 6 15.7 at 9 mo, P = 0.02) and no difference in ESS scores (7.2 6
4.3 vs. 5.9 6 3.5 at 9 mo, P = 0.98). Changes in AHI varied
linearly with changes in BMI, with a 3.3% (SEM, 1.5%) reduction in
AHI for every 1% reduction in BMI and no difference in slope by
treatment.
To our knowledge, this is the ﬁrst randomized trial to compare
bariatric surgery and CPAP as initial treatment for OSA. We found
that the effective AHI at 9 months was signiﬁcantly lower with
CPAP, and there was no difference in daytime sleepiness between
groups. Neither of these ﬁndings supported our hypotheses. The
rate of OSA resolution with LGB was fairly low, in keeping with
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Exclusion criteria
Did not have severe symptomatic OSA n =24
Did not have class ll/lll obesity n=57
Insurance issues n= 18
Prior CPAP n = 113
Prior bariatric surgery n = 12
Pregnant or planning n= 1
Hypoventilation syndrome n=4
Drowsy driving n = 45
Smoking n = 30
Venothromboembolism n=15
Congestive heart failure n= 80
Impaired functional status n =3
Outcome interpretation n = 33
Other unstable medical condition n=24

Other reasons
Medical chart review n= 973

Not interested in research n =96
Time commitment n=18
Wanted CPAP n=206
Wanted surgery n =26
Travel difficulties n=3
Wanted alternative OSA treatment n = 10
Did not want to treat OSA n =8
Participating in other research study n = 1
Passive refusal n=47

Preliminary eligibility met n= 504

Family did not support n = 1
Wanted CPAP n=15
Wanted surgery n=4
Uncomfortable with randomization n= 1
Financial concerns n =2
Time commitment n= 2
PCP non-equipoise n=1
Wanted both CPAP and surgery n =1
Passive refusal n=2

Attended screening visit n=89

Participant withdrew consent n =3
Physician withdrawal n =1

Signed consent form n=53

Unstable medical condition n =3
Smoking n =1
Did not have class II/III obesity n=1
Drowsy driving n = 1
Insurance issues n = 1

Final eligibility met n =82

Randomized n=49

LGB n =28
Age [years] 50.7±9.2
Males n =16 (57%)
Non-Hispanic White ethnicity/race n=21 {75%}

CPAP n =21
Age (years) 46.3±10.5
Males n= 12 (57%)
Non-Hispanic White ethnicity/race n= 14 {67%}
Voluntary drop-out n=1
Lost to follow-up n=2

Voluntary drop-out n=3

9-month follow up n=25

9-month follow up n=18
Voluntary drop-out n=1
Lost to follow-up n=1

Voluntary drop-out n=1

18-month follow up n=24

18-month follow up n=16

Figure 1. Consolidated Standards of Reporting Trials diagram. The numbers in the boxes represent sample size according to randomized arm. Age is
presented as mean 6 SD. CPAP = continuous positive airway pressure; LGB = laparoscopic gastric banding; OSA = obstructive sleep apnea; PCP =
primary care provider.

prior trials that evaluated the effects of LGB on AHI (5, 6).
Compared with prior trials, the impact of LGB on average weight
in our study was modest, at just under 10 kg. Despite this result,
the mean reduction in AHI of 17.4 events/h in the surgery group
is similar to the improvements observed in prior studies (5, 6).
The linear relationship between changes in BMI and AHI supports
the hypothesis that LGB improves OSA via weight loss.
Prior studies that compared medical treatment and surgical
treatment of OSA were limited by failing to account for suboptimal
adherence to CPAP. A strength of our study is the focus on effective
AHI as a primary outcome. The comparative-effectiveness framework
increases generalizability to standard local practice. High attrition
rates are often a concern in comparative-effectiveness studies;
however, our dropout rate of 12% is modest and unlikely to be a
major source of bias.
Important limitations should be considered. First, an
unexpectedly high number of patients did not undergo LGB, as
the majority of these individuals opted to use CPAP. This, in large
part, reﬂects the realities of bariatric surgery referral, with patient
Correspondence

ambivalence, nonadherence to preoperative guidelines, detection
of surgical contraindications, and insurance barriers all limiting
the implementation of surgery. Given our results indicating increased
effectiveness of CPAP, the crossovers from LGB to CPAP suggest
that our intention-to-treat analyses may in fact underestimate the
difference in effective AHI between CPAP and LGB. Our results
indicating greater improvement with CPAP in per-protocol
analyses support the robustness of our ﬁndings. It is possible that
our results overestimate the beneﬁt of CPAP, if those most likely
to beneﬁt from LGB did not undergo surgery. We believe this
scenario to be unlikely. Finally, it is possible that our follow-up
duration was not long enough to allow the full beneﬁts of LGB to
occur.
The superior impact of CPAP on the effective AHI means that,
in our opinion, CPAP is a more effective treatment than LGB for
controlling OSA. This ﬁnding does not eliminate weight-loss
therapy, whether behavioral or surgical, as an adjunctive treatment.
Of note, two recent randomized trials of behavioral weight-loss
therapy in OSA indicated that the beneﬁcial effects of weight loss on
1081
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Table 1. Measures of Anthropometry and Sleep at Baseline, 9 Months, and 18 Months, according to Randomized Arm (Intention to
Treat)

Baseline
(n = 28)

Randomized LGB
9 mo
18 mo
(n = 25)
(n = 24)

Baseline
(n = 21)

Randomized CPAP
9 mo
18 mo
(n = 18)
(n = 16)

Anthropometry
39.1 6 2.9
35.9 6 3.5*
35.7 6 3.9*
38.7 6 3.1
37.4 6 3.7
37.4 6 4.5
BMI, kg/m2
Weight, kg
115.4 6 16.9 106.7 6 18.0* 106.1 6 18.0* 111.1 6 16.1 106.0 6 13.4 106.3 6 16.0
Neck circumference, cm 40.9 6 4.3
40.1 6 4.8
40.6 6 3.8
42.6 6 4.4
41.5 6 4.1*
42.3 6 3.9
Waist circumference, cm 123.5 6 10.3 116.4 6 13.2* 115.0 6 12.5* 120.5 6 8.1 115.7 6 11.4* 116.5 6 10.2*
Hip circumference, cm 127.5 6 8.6 120.8 6 8.4* 120.8 6 8.9* 124.1 6 7.4 116.0 6 16.9* 120.7 6 9.2
Sleep measures
AHI off CPAP treatment, 51.5 6 23.5 39.3 6 26.4* 34.1 6 24.6* 47.5 6 31.5 34.7 6 31.6
36.4 6 23.2
events/h
†
N/A
29.5 6 23.4
20.9 6 16.0
N/A
20.0 6 25.3
21.4 6 17.6
Effective AHI, events/h
ESS, out of 24
10.4 6 4.2
7.6 6 4.7*
8.0 6 4.5*
9.8 6 5.0
7.8 6 4.8
6.2 6 3.7*
Effective AHI ,5
N/A
1 (4%)
3 (13%)
N/A
4 (22%)
3 (19%)
events/h, n (%)
Effective AHI ,15
N/A
7 (28%)
11 (46%)
N/A
11 (61%)
8 (50%)
events/h, n (%)
CPAP adherence,
4.5 6 2.7
4.7 6 2.8
h/night

Adjusted
P Values (between
Arms)
9 mo

18 mo

0.01
0.45
0.04
0.70
0.36

0.09
0.60
0.08
0.52
0.80

0.28

0.93

0.02
0.53
0.14

0.89
0.19
0.67

0.06

1.00

N/A

N/A

Definition of abbreviations: AHI = apnea–hypopnea index; BMI = body mass index; CPAP = continuous positive airway pressure; ESS = Epworth
Sleepiness Scale; LGB = laparoscopic gastric banding; N/A = not applicable.
Data are presented as mean 6 SD unless otherwise indicated. Outcome data are not transformed.
Between-arm P values for continuous outcomes were obtained from models adjusted for stratification factors (recruitment clinic, baseline BMI category,
and sex). AHI was log-transformed at 9 months only. BMI was log-transformed at 18 months only. Hip circumference, effective AHI, and ESS scores were
log-transformed at 9 months and 18 months.
*P , 0.05 testing if the within-arm difference from baseline was different from zero (within-arms t test or a signed-rank test depending on distribution).
†
Note that an effective AHI was calculated for any patient using CPAP regardless of randomized arm.

OSA severity may persist despite weight regain (7, 8). Furthermore,
weight-loss interventions may have greater beneﬁt on cardiovascular
risk reduction than CPAP (9–11). Finally, our results do not
provide insights into how more aggressive bariatric procedures,
such as gastric bypass and sleeve gastrectomy, may compare with
CPAP in the management of OSA. n

Author disclosures are available with the text of this letter at
www.atsjournals.org.
Jessie P. Bakker, Ph.D.
Ali Tavakkoli, M.D.
Brigham and Women’s Hospital
Boston, Massachusetts
and
Harvard Medical School
Boston, Massachusetts
Michael Rueschman, M.P.H.
Brigham and Women’s Hospital
Boston, Massachusetts
Wei Wang, Ph.D.
Brigham and Women’s Hospital
Boston, Massachusetts
and
Harvard Medical School
Boston, Massachusetts

1082

Robert Andrews, M.D.
Hofstra-Northwell School of Medicine
Hempstead, New York
Atul Malhotra, M.D.
Robert L. Owens, M.D.
University of California, San Diego
San Diego, California
Amit Anand, M.D.
Katherine A. Dudley, M.D.
Harvard Medical School
Boston, Massachusetts
and
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Sanjay R. Patel, M.D.
University of Pittsburgh
Pittsburgh, Pennsylvania

References
1. Boyd SB, Upender R, Walters AS, Goodpaster RL, Stanley JJ, Wang L,
et al. Effective apnea-hypopnea index (“effective AHI”): a new measure
of effectiveness for positive airway pressure therapy. Sleep 2016;39:
1961–1972.
2. Boyd SB, Walters AS. Effectiveness of treatment apnea-hypopnea
index: a mathematical estimate of the true apnea-hypopnea
index in the home setting. J Oral Maxillofac Surg 2013;71:
351–357.

American Journal of Respiratory and Critical Care Medicine Volume 197 Number 8 | April 15 2018

CORRESPONDENCE
3. Bianchi MT, Alameddine Y, Mojica J. Apnea burden: efﬁcacy versus
effectiveness in patients using positive airway pressure. Sleep Med
2014;15:1579–1581.
4. Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss
on measures of obstructive sleep apnea: a meta-analysis. Am J Med
2009;122:535–542.
5. Dixon JB, Schachter LM, O’Brien PE, Jones K, Grima M, Lambert G, et al.
Surgical vs conventional therapy for weight loss treatment of obstructive
sleep apnea: a randomized controlled trial. JAMA 2012;308:1142–1149.
6. Feigel-Guiller B, Drui D, Dimet J, Zair Y, Le Bras M, Fuertes-Zamorano N,
et al. Laparoscopic gastric banding in obese patients with sleep
apnea: a 3-year controlled study and follow-up after 10 years. Obes
Surg 2015;25:1886–1892.
7. Kuna ST, Reboussin DM, Borradaile KE, Sanders MH, Millman RP,
Zammit G, et al.; Sleep AHEAD Research Group of the Look
AHEAD Research Group. Long-term effect of weight loss on
obstructive sleep apnea severity in obese patients with type
2 diabetes. Sleep 2013;36:641–649A.
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Inverse Relationship between Soluble RAGE and Risk
for Bronchopulmonary Dysplasia
To the Editor:
Bronchopulmonary dysplasia (BPD), the most common form of
chronic lung disease during childhood, leads to substantial
morbidity in premature infants (1). Inﬂammation is a major
antecedent risk factor for BPD, yet the molecular mechanisms that
regulate the inﬂammatory cascade in the preterm lung are not well
Supported by Prematurity and Respiratory Outcomes Program/NIH grant
U01-HL101456 (J.L.A.), Prematurity and Respiratory Outcomes
Program/NIH scholars grant U01-HL101794 (J.T.B.), and NIH grants K12
HD087023 (Research Scholar, J.T.B.), K08 HL133484 (J.T.B.), and
HL119503 (L.R.Y.). Study data were collected and managed using REDCap
electronic data capture tools hosted at Vanderbilt University (Vanderbilt
Institute for Clinical and Translational Research; supported by grant
UL1TR000445 from the National Center for Advancing Translational
Sciences/NIH).
Author Contributions: J.T.B., T.S.B., and L.R.Y. conceived the study; J.T.B.,
J.L.A., P.E.M., T.S.B., and L.R.Y. planned the work; R.v.d.M. and J.T.B.
performed the laboratory work; J.T.B., J.C.S., E.J.P., and J.M.S. contributed
to analysis and interpretation of the data; S.S. coordinated the collection of
tracheal aspirate samples; J.T.B., P.E.M., J.L.A., T.S.B., and L.R.Y. drafted
the manuscript. All authors approved the final manuscript.
Originally Published in Press as DOI: 10.1164/rccm.201707-1445LE on
October 16, 2017
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described (2). Further, biomarkers that accurately identify infants
at high risk for BPD are also not well deﬁned.
RAGE (receptor for advanced glycation end products) is a
membrane-spanning receptor that mediates inﬂammatory
signaling in multiple organs. In the lung, RAGE is predominantly
expressed on alveolar epithelial cells, where it binds a variety of
ligands, including AGEs (advanced glycation end products),
resulting in activation of inﬂammatory signaling pathways (3).
Along with its full-length form, RAGE also exists in soluble forms
(sRAGE [soluble RAGE]) produced by alternate splicing
(esRAGE [endogenous sRAGE]) or by proteolytic cleavage of the
extracellular portion of RAGE (cleaved sRAGE). Soluble forms of
RAGE possess a ligand-binding domain but lack transmembrane
and cytoplasmic domains, which prevents them from activating
intracellular signaling (4). Thus, sRAGE functions as a “decoy”
to bind and sequester RAGE ligands, thereby attenuating
inﬂammation.
Reduced levels of sRAGE are found in chronic pulmonary
conditions such as chronic obstructive pulmonary disease (COPD)
and neutrophilic asthma (5). Expression of sRAGE in the
preterm lung and its relationship with BPD have not been well
characterized. Therefore, we performed a study in which we
quantiﬁed the levels of sRAGE in the lungs of intubated
preterm infants and examined the association between these
measurements and subsequent development of severe BPD. Some
of the results of these studies have been previously published as an
abstract (6).
Methods

Preterm infants born between the ages of 23 0/7 and 28 6/7 weeks
were prospectively enrolled in the PROP (Prematurity and
Respiratory Outcome Program) study at Vanderbilt University
Medical Center from September 2011 to December 2014 (7).
Infants who remained intubated at 1 week of age and had tracheal
aspirate (TA) samples collected at that time were eligible for
inclusion in this single-center study. Concentrations of esRAGE
and total sRAGE in TA samples were measured using
commercially available ELISA kits (B-Bridge International
[esRAGE] and R&D Systems [sRAGE]) and normalized to the
total protein content of each sample.
Results

Forty-nine eligible preterm infants had an archived week 1 TA
sample of sufﬁcient volume. One infant with a congenital airway
anomaly and three infants with TA samples containing low
protein content (,0.1 mg/ml) were excluded. Of the remaining
45 infants, 15 were diagnosed with severe BPD, deﬁned as the
need for mechanical ventilation or signiﬁcant noninvasive
positive pressure support (.2 L/min Vapotherm [Vapotherm]
or continuous positive airway pressure with an FIO2 . 0.3) at 36
weeks postmenstrual age (PMA). Four infants who died before 36
weeks PMA were included in the severe-BPD group. Twenty-six
premature infants without severe BPD or death comprised the
control group. Table 1 displays the distribution of clinical variables
for infants in the two groups.
Levels of esRAGE and total sRAGE were lower in the TAs
of infants with severe BPD compared with controls (Figures 1A
and 1B), irrespective of whether the four infants who died before
1083

